Shots:

• The P-II trial will evaluate the efficacy- safety- and tolerability of KN046 + Pfizer's Inlyta (axitinib) as a 1L treatment of NSCLC. The 1EPs of the study are ORR
• The P-II trial of KN046 for advanced NSCLC has demonstrated superior tolerability- safety- as well as PFS and OS. Following the results- the companies have initiated P-III ENREACH-LUNG-01 trial to explore new 1L standard therapies for lung cancer
• In Mar’2020- the companies collaborated to evaluate KN026 in + Ibrance (palbociclib) and have received NMPA’s IND approval in Dec’2020

  Ref: PRN Asia | Image: Pfizer